A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Ustekinumab

Criteria

Inclusion Criteria:

• Have had a diagnosis of plaque-type psoriasis at least 6 months

• Plaque-type psoriasis covering at least 10% of total body surface areas

• Psoriasis area-and-severity index score of 12 or greater

• Considered by treating dermatologist to be a candidate for phototherapy or systemic treatment of psoriasis

• Women of childbearing potential and all men must agree to use adequate birth control measures

• Have no history of latent or active tuberculosis

Exclusion Criteria:

• Currently have nonplaque forms of psoriasis or drug-induced psoriasis

• Women who are pregnant or nursing, or men and women planning pregnancy while enrolled in the study

• Patients who have a history of chronic or recurrent infectious disease or who have or have had a serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months

• Patients who have or ever have had a nontuberculous mycobacterial infection or opportunistic infection

• Patients known to be infected with human immunodeficiency virus, hepatitis B, or hepatitis C

• Patients who have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease

• Have any known malignancy or have a history of malignancy within the previous 5 years (with the exception of basal cell carcinoma of the skin that has been treated with no evidence of recurrence)